|
gptkbp:instance_of
|
gptkb:Clinical_Trials
|
|
gptkbp:aims_to
|
reduce retinal edema
|
|
gptkbp:analyzes
|
treatment efficacy
|
|
gptkbp:collaborated_with
|
academic institutions
research institutions
|
|
gptkbp:completed
|
gptkb:2013
|
|
gptkbp:conducted
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
clinical research organizations
multiple centers
|
|
gptkbp:evaluates
|
quality of life
|
|
gptkbp:focuses_on
|
gptkb:Ophthalmology
|
|
gptkbp:has_primary_outcome
|
change in visual acuity
|
|
gptkbp:has_sample_size
|
over 500 participants
|
|
gptkbp:has_secondary_outcome
|
reduction in retinal thickness
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
VEGF Trap-Eye Study
|
|
gptkbp:includes
|
placebo group
|
|
gptkbp:investigates
|
gptkb:VEGF_Trap-Eye
|
|
gptkbp:involves
|
patients with diabetic macular edema
|
|
gptkbp:involves_age_group
|
adults
|
|
gptkbp:is_analyzed_in
|
statistical methods
patient demographics
cost-effectiveness
|
|
gptkbp:is_associated_with
|
improved patient outcomes
|
|
gptkbp:is_cited_in
|
subsequent research studies
|
|
gptkbp:is_compared_to
|
VEGF Trap-Eye and ranibizumab
|
|
gptkbp:is_discussed_in
|
gptkb:literature
medical reviews
|
|
gptkbp:is_documented_in
|
clinical trial registries
|
|
gptkbp:is_ethically_approved_by
|
institutional review board
|
|
gptkbp:is_evaluated_by
|
safety and efficacy
clinical outcomes
long-term effects
|
|
gptkbp:is_funded_by
|
gptkb:National_Eye_Institute
|
|
gptkbp:is_influential_in
|
ophthalmic drug development
|
|
gptkbp:is_led_by
|
principal investigator
|
|
gptkbp:is_monitored_by
|
gptkb:data_safety_monitoring_board
|
|
gptkbp:is_part_of
|
clinical research initiatives
VEGF Trap clinical program
VEGF Trap clinical trials
VEGF Trap development program
VEGF Trap research portfolio
|
|
gptkbp:is_referenced_in
|
gptkb:guidelines
|
|
gptkbp:is_related_to
|
retinal diseases
|
|
gptkbp:is_relevant_to
|
patient care
ophthalmology research
|
|
gptkbp:is_reviewed_by
|
systematic reviews
|
|
gptkbp:is_supported_by
|
grants
pharmaceutical companies
|
|
gptkbp:is_used_to
|
inform treatment protocols
|
|
gptkbp:is_utilized_by
|
gptkb:healthcare_professionals
|
|
gptkbp:measures
|
visual acuity
|
|
gptkbp:outcome
|
improved vision
|
|
gptkbp:presented_by
|
medical conferences
|
|
gptkbp:published_by
|
peer-reviewed journals
|
|
gptkbp:published_in
|
gptkb:Ophthalmology
|
|
gptkbp:registration
|
gptkb:Clinical_Trials.gov
|
|
gptkbp:reported_by
|
gptkb:academic_journals
gptkb:guidelines
|
|
gptkbp:reports_to
|
safety outcomes
|
|
gptkbp:result
|
gptkb:2014
|
|
gptkbp:sponsored_by
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:started_in
|
gptkb:2010
|
|
gptkbp:targets
|
gptkb:vascular_endothelial_growth_factor
|
|
gptkbp:uses
|
randomized controlled trial design
|
|
gptkbp:utilizes
|
intravitreal injections
|
|
gptkbp:bfsParent
|
gptkb:Eylea
|
|
gptkbp:bfsLayer
|
5
|